Challenges for cardiovascular drug research

Cardiovascular Drug Reviews

Volumn 25, Issue 3, 2007, Pages 205-209

  Scriabine, Alexander ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; AMBRISENTAN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIFIBROTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BOSENTAN; CARDIOVASCULAR AGENT; CYT006 ANGQB; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENRASENTAN; FIBRINOLYTIC AGENT; NITRATE; NITRIC OXIDE DONOR; ROFECOXIB; ROSIGLITAZONE; ROTIGAPTIDE; SILDENAFIL; SITAXSENTAN; UNCLASSIFIED DRUG; VACCINE; VASODILATOR AGENT;

ACUTE HEART INFARCTION; ANTIHYPERTENSIVE THERAPY; BLEEDING; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAUSE OF DEATH; CHRONIC DISEASE; CORONARY RISK; DRUG COST; DRUG EFFICACY; DRUG RESEARCH; DRUG SAFETY; DRUG TARGETING; EDITORIAL; FOOD AND DRUG ADMINISTRATION; GENE EXPRESSION; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART INFARCTION; HEART VENTRICLE FIBRILLATION; HYPERTENSION; ISCHEMIC HEART DISEASE; KIDNEY FAILURE; LIVER CIRRHOSIS; LUNG FIBROSIS; MEDICAL LITERATURE; MORBIDITY; MORTALITY; PREVENTIVE MEDICINE; PRIORITY JOURNAL; PUBLICATION; PULMONARY HYPERTENSION; STEM CELL TRANSPLANTATION; STROKE; STROKE PRONE SPONTANEOUSLY HYPERTENSIVE RAT; SUDDEN DEATH; SYSTOLIC HYPERTENSION;

EID: 35148897174     PISSN: 08975957     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-3466.2007.00015.x     Document Type: Editorial

References (15)

1. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, Lines C, Ridell R, Morton D, Lanas A, et al 2005) Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 352 : 1092 1102.
2. Cytos Biotechnology AG (2007) http://www.cytos.com
3. Fiaccavento R, Carotenuto F, Minieri M, Masuelli L, Vecchini A, Bei R, Modesti A, Binaglia L, Fusco A, Bertoli A, et al 2006) Alpha-linolenic acid-enriched diet prevents myocardial damage and expands longevity in cardiomyopathic hamsters. Am J Pathol 169 : 1913 1924.
4. 1 receptors increases survival of obese Zucker rats. Eur J Pharmacol 534 : 271 279.
5. Kaye DM, Krum H (2007) Drug discovery for heart failure: A new era or the end of the pipeline? Nat Rev/Drug Discov 6 : 127 139.
6. Kazda S, Garthoff G, Luckhaus G, Nash G (1982) Prevention of cerebrovascular lesions and mortality in stroke-prone spontaneously hypertensive rats by the calcium antagonist, nimodipine. In : Calcium modulators, Godfraind T, Albertini A, Paoletti R, eds. Amsterdam : Elsevier Biomedical, pp. 155 168.
7. Lloyd-Jones DM, Evans JC, Levy D (2005) Hypertension in adults across the age spectrum: Current outcomes and control in the community. JAMA 294 : 466 472.
8. Mattera GG, Lo Giudice P, Francesca MP, Vanoli E, Gagnol J-P, Borsini F, Carminati P (2007) Istaroxime: A new luso-inotropic agent for heart failure. Am J Cardiol 99 : 33A 40A.
9. McKay MJ, Gaballa MA (2001) Gene therapy in vascular diseases. Cardiovasc Drug Revs 19 : 245 262.
10. Nattel S, Carlsson L (2006) Innovative approaches to anti-arrhythmic drug therapy. Nat Rev/Drug Discov 5 : 1034 1049.
11. Nissen SE, Wolski K (2007) Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356 : 2457 2471.
12. Scriabine A (2007) Hypertension. In : Comprehensive Medicinal Chemistry II, Taylor JB, Triggle DJ, eds. Amsterdam : Elsevier, 6 : 705 728.
13. Shin DD, Brandimarte E, De Luca L, Sabbah H, Fonarow N, Fillippatos G, Komajda M Gheorghiade M (2007) Review of current and investigational pharmacologic agents for acute heart failure syndromes. Am J Cardiol 99 : 4A-23A.
14. Sunkomat JNE, Gaballa MA (2003) Cardivasc Drug Revs 21 : 327 342.
15. Tomita N, Morishita R (2004) Antisense oligonucleotides as a powerful molecular strategy for gene therapy in cardiovascular diseases. Curr Pharm Design 10 : 797 803.